STC-15 | METTL3 inhibitor

CAS:
 2648257-56-9
Catalog Number:
 10-4874
STC-15 chemical structure

Available Options

Size:PriceQuantity 
5 mg$80.00
25 mg$275.00
Request Quote / Bulk / Custom Size
Product Inquiry

STC-15 (2648257-56-9) is an orally bioavailable inhibitor of the RNA methyltransferase METTL3.  Inhibits acute myeloid leukemia growth and induces anti-cancer immunity via activation of double strand RNA sensing machinery and interferon signaling.  STC-15 synergizes with radiation therapy and T cell checkpoint blockade and enhances the cytotoxicity of doxorubicin chemotherapy.

References/Citations:

  1. Ofir-Rosenfeld et al. (2022), STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergizes with T cell checkpoint blockade; Eur. J. Cancer 174 Suppl. 1 S123
  2. Ofir-Rosenfeld et al. (2023), STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment; Mol. Cancer Ther. 22 C077
2648257-56-9, METTL3 inhibitor, STC-15, STC-15 supplier, STC15
CAS:
2648257-56-9
Catalog Number:
10-4874
Activity:
METTL3 inhibitor
Chemical Names:
N-[[2-[(Cyclobutylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide
Molecular Weight:
415.50
Molecular Formula:

C24H25N5O2

Solubility:
Soluble in DMSO (25 mg/ml)
Physical Properties:
Pale yellow solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

STC-15 (2648257-56-9) is an orally bioavailable inhibitor of the RNA methyltransferase METTL3.  Inhibits acute myeloid leukemia growth and induces anti-cancer immunity via activation of double strand RNA sensing machinery and interferon signaling.  STC-15 synergizes with radiation therapy and T cell checkpoint blockade and enhances the cytotoxicity of doxorubicin chemotherapy.

References/Citations:

  1. Ofir-Rosenfeld et al. (2022), STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergizes with T cell checkpoint blockade; Eur. J. Cancer 174 Suppl. 1 S123
  2. Ofir-Rosenfeld et al. (2023), STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment; Mol. Cancer Ther. 22 C077

STEM CELL

BOGO